Besides, antagonism therapy against CCR2 strikingly suppressed estrogen-triggered breast cancer growth, vascularization, macrophage infiltration and metastasis in xenograft tumor models, suggesting a critical role of CCL2-CCR2 axis in HR+ tumor progression. This evidence concerns the gene CCR2 and breast cancer.